How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
AI agents are not yet creative enough to carry out genuinely innovative open-ended AI research, it seems. The AI industry’s boldest promise right now is that AI will soon improve itself, with almost ...
Find out why the results may temper claims that recursive self-improvement is on the horizon. —Michelle Kim This summer has been a scorcher for much of the Northern Hemisphere. June and July marked ...
The last time 96-year-old Audrey Staniland was assessed for in-home aged care funding was with a human clinician more than a decade ago. When her daughter applied for a reassessment late last year, ...
Machine learning is the ability of a machine to improve its performance based on previous results. Machine learning methods enable computers to learn without being explicitly programmed and have ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results